Abstract
Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53ΔE6 and p53β, we identified p53ζ, p53δ and p53ɛ, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53δ expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032). Also, p53δ expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121–3.065, P=0.016; and hazard ratio 1.937, 95% confidence interval 1.177–3.186, P=0.009, respectively). p53β expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P=0.002 and P=0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P=0.049). ΔN′p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anczuków O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM et al. (2008). Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29: 65–73.
Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP et al. (2008). Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659–1668.
Boldrup L, Bourdon JC, Coates PJ, Sjöström B, Nylander K . (2007). Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43: 617–623.
Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. (2005). P53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122–2137.
Casciano I, Banelli B, Croce M, Allemani G, Ferrini S, Tonini GP et al. (2002). Epigenetic control of the p73 gene in neuroblastoma. Cell Death Differ 9: 343–345.
Chan WM, Siu WY, Lau A, Poon RY . (2004). How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24: 3536–3551.
Chow VT, Quek HH, Tock EP . (1993). Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett 73: 141–148.
Concin N, Stimpel M, Zeillinger C, Wolff U, Hefler L, Sedlak J et al. (2003). Role of p53 in G2/M cell cycle arrest and apoptosis in response to γ-irradiation in ovarian carcinoma cell lines. Int J Oncol 22: 51–57.
Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H et al. (2004). Transdominant deltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Role for their evidence as epigenetic p53 inhibitors in vivo. Cancer Res 64: 2449–2460.
Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. (2005). Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372–8383.
Cui R, He J, Mei R, de Fromentel C, Martel-Planche G, Taniere P et al. (2005). Expression of p53, p63 and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem Biophys Res Commun 336: 339–345.
Duddy PM, Hanby AM, Barnes DM, Camplejohn RS . (2000). Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. J Mol Diagn 2: 139–144.
Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K . (2008). Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 44: 156–161.
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963–3967.
Fontemaggi G, Aymone Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G et al. (2001). The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 21: 8461–8470.
Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, Stamm S et al. (2004). Expression of splicing factors in human ovarian cancer. Oncol Rep 11: 1085–1090.
Graupner V, Schulze-Osthoff K, Essmann R, Jänicke RU . (2009). Functional characterization of p53β and p53γ, two isoforms of the tumor supressor p53. Cell Cycle 8: 1238–1248.
Guan M, Chen Y . (2005). Aberrant expression of deltaNp73 in benign and malignant tumours of the prostate: a correlation with Gleason score. J Clin Pathol 58: 1175–1179.
Holmila R, Fouquet C, Cadranel J, Zalcman G, Soussi T . (2003). Splice mutations in the p53 gene: case report and review of the literature. Hum Mut 21: 101–102.
Jänicke RU, Graupner V, Budach W, Essmann F . (2009). The do's and don'ts of p53 isoforms. Biol Chem 390: 951–963.
Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT . (1994). Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 9: 97–102.
Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP et al. (2007). The diploid genome sequence of an individual human. PLoS Biol 5: e254.
Magnusson KP, Sandstrom M, Stahlberg M, Larsson M, Flygare J, Hellgren D et al. (2000). P53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene 246: 247–254.
Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R et al. (2008). Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 44: 131–141.
Mobus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W et al. (1992). Morphological, immunohistochemical and biochemical characterization of 6 newly established ovarian carcinoma cell lines. Int J Cancer 52: 76–84.
Oswald C, Stiewe T . (2008). In good times and bad: p73 in cancer. Cell Cycle 7: 1726–1731.
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622–629.
Slade N, Zaika AI, Erster S, Moll UM . (2004). DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ 11: 357–360.
Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM . (2004). Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 10: 626–633.
Yaginuma Y, Westphal H . (1992). Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196–4199.
Yu Y, Baron V, Mercola D, Mustelin T, Adamson ED . (2007). A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 14: 436–446.
Acknowledgements
We thank Andrea Wolf for her technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Hofstetter, G., Berger, A., Fiegl, H. et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer. Oncogene 29, 1997–2004 (2010). https://doi.org/10.1038/onc.2009.482
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.482
Keywords
This article is cited by
-
It is not all about the alpha: elevated expression of p53β variants is associated with lower probability of survival in a retrospective melanoma cohort
Cancer Cell International (2023)
-
Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines
Scientific Reports (2019)
-
Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
Scientific Reports (2019)
-
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma
BMC Cancer (2018)
-
A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation
Mammalian Genome (2018)